Japan Helps Bayer’s Eylea Sales To Sparkle
Strong Quarter For German Major
Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.
You may also be interested in...
Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary
Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.
The FIGARO-DKD cardiovascular outcomes trial showed finerenone reduced composite risk of CV death or non-fatal events in CKD patients with Type 2 diabetes, including earlier-stage patients.